These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 23148845)

  • 1. A gender-related action of IFNbeta-therapy was found in multiple sclerosis.
    Contasta I; Totaro R; Pellegrini P; Del Beato T; Carolei A; Berghella AM
    J Transl Med; 2012 Nov; 10():223. PubMed ID: 23148845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological study of IFNbeta-1a-treated and untreated multiple sclerosis patients: clarifying IFNbeta mechanisms and establishing specific dendritic cell immunotherapy.
    Berghella AM; Totaro R; Pellegrini P; Contasta I; Russo T; Carolei A; Adorno D
    Neuroimmunomodulation; 2005; 12(1):29-44. PubMed ID: 15756051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD30 antigen and multiple sclerosis: CD30, an important costimulatory molecule and marker of a regulatory subpopulation of dendritic cells, is involved in the maintenance of the physiological balance between TH1/TH2 immune responses and tolerance. The role of IFNbeta-1a in the treatment of multiple sclerosis.
    Pellegrini P; Totaro R; Contasta I; Berghella AM; Carolei A; Adorno D
    Neuroimmunomodulation; 2005; 12(4):220-34. PubMed ID: 15990453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble CD30: a biomarker for evaluating the clinical risk versus benefit of IFNbeta1A treatment in multiple sclerosis patients.
    Contasta I; Totaro R; Berghella AM; Pellegrini P; Del Beato T; Carolei A; Adorno D
    Int J Immunopathol Pharmacol; 2010; 23(1):213-26. PubMed ID: 20378007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokines and disability in interferon-β-1b treated and untreated women with multiple sclerosis.
    Trenova AG; Slavov GS; Manova MG; Kostadinova II
    Arch Med Res; 2014 Aug; 45(6):495-500. PubMed ID: 25130430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IFN-beta inhibits human Th17 cell differentiation.
    Ramgolam VS; Sha Y; Jin J; Zhang X; Markovic-Plese S
    J Immunol; 2009 Oct; 183(8):5418-27. PubMed ID: 19783688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
    Bongioanni P; Romano MR; Boccardi B; Lombardo F; Moscato G; Mosti S; Baldini C; Nuti S; Meucci G; Rossi B
    Rev Neurol; 1999 Nov 16-30; 29(10):893-9. PubMed ID: 10637835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T Helper Cells: The Modulators of Inflammation in Multiple Sclerosis.
    Kunkl M; Frascolla S; Amormino C; Volpe E; Tuosto L
    Cells; 2020 Feb; 9(2):. PubMed ID: 32093011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
    Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
    J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
    Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and laboratory study of pro-inflammatory and antiinflammatory cytokines in women with multiple sclerosis.
    Trenova AG; Manova MG; Kostadinova II; Murdjeva MA; Hristova DR; Vasileva TV; Zahariev ZI
    Folia Med (Plovdiv); 2011; 53(2):29-35. PubMed ID: 21797104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex- and species-specific contribution of CD99 to T cell costimulation during multiple sclerosis.
    Winschel I; Willing A; Engler JB; Walkenhorst M; Meurs N; Binkle-Ladisch L; Woo MS; Pfeffer LK; Sonner JK; Borgmeyer U; Hagen SH; Grünhagel B; Claussen JM; Altfeld M; Friese MA
    Biol Sex Differ; 2024 May; 15(1):41. PubMed ID: 38750588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of immunomodulatory treatment on leukocyte cytokine production in multiple sclerosis patients and healthy donors.
    Reske D; Thomas AV; Petereit HF; Fink GR; Schroeter M
    Neuroimmunomodulation; 2009; 16(6):385-91. PubMed ID: 19609087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects.
    González-Oria MC; Márquez-Coello M; Girón-Ortega JA; Argente J; Moya M; Girón-González JA
    J Neuroimmune Pharmacol; 2019 Sep; 14(3):413-422. PubMed ID: 30649665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple sclerosis: levels of interleukin-10-secreting blood mononuclear cells are low in untreated patients but augmented during interferon-beta-1b treatment.
    Ozenci V; Kouwenhoven M; Huang YM; Xiao B; Kivisäkk P; Fredrikson S; Link H
    Scand J Immunol; 1999 May; 49(5):554-61. PubMed ID: 10320650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-Beta Therapy of Multiple Sclerosis Patients Improves the Responsiveness of T Cells for Immune Suppression by Regulatory T Cells.
    Trinschek B; Luessi F; Gross CC; Wiendl H; Jonuleit H
    Int J Mol Sci; 2015 Jul; 16(7):16330-46. PubMed ID: 26193267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.
    Durelli L; Conti L; Clerico M; Boselli D; Contessa G; Ripellino P; Ferrero B; Eid P; Novelli F
    Ann Neurol; 2009 May; 65(5):499-509. PubMed ID: 19475668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment.
    Ozenci V; Kouwenhoven M; Huang YM; Kivisäkk P; Link H
    Clin Exp Immunol; 2000 Apr; 120(1):147-53. PubMed ID: 10759776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormal levels of interferon-gamma receptors in active multiple sclerosis are normalized by IFN-beta therapy: implications for control of apoptosis.
    Ahn J; Feng X; Patel N; Dhawan N; Reder AT
    Front Biosci; 2004 May; 9():1547-55. PubMed ID: 14977566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender-specific cytokine pathways, targets, and biomarkers for the switch from health to adenoma and colorectal cancer.
    Pellegrini P; Contasta I; Del Beato T; Ciccone F; Berghella AM
    Clin Dev Immunol; 2011; 2011():819724. PubMed ID: 22235223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.